Dyne Therapeutics(NASDAQ) DYN

Market Cap$2.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-35%
5 Year+0%
1 Year+18%
1 Month-36%
Premium Feature
Moneyball Superscore
73/100
$15.41
-0.19%
-0.03Today
Dyne Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 15.442026-10-05
Dyne Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.51%USD 16.342026-09-28
1 month-36.41%USD 24.282026-09-04
3 month-35.21%USD 23.832026-07-07
Year to date-21.06%USD 19.562025-12-31
1 year+18.22%USD 13.062025-10-03
3 year+64.08%USD 9.412023-10-06
5 year+0.19%USD 15.412021-10-06
Since inception-35.4%USD 23.902020-09-17

Dyne Therapeutics Financials at a Glance

Market Cap

$2.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$519.41

EPS (TTM)

-$3.33

P/E Ratio

-4.63

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$15.41

Volume

819,994.562

Open

$15.50

Previous Close

$15.44

Daily Range

$14.93 - $15.50

52-Week Range

$12.77 - $27.31

Estimated Earnings Date

N/A

About Dyne Therapeutics

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Industry

Biotechnology

Employees

289

CEO

John G. Cox, MBA

DYN Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-81.57%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-21.60%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$2.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

186.75M

Volume

819.99K

Avg. Volume

2.75M

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Dyne Therapeutics Performance Analysis

Dyne Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Dyne Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.2310.3%
20232023-12-31USD -3.9522.2%
20242024-12-31USD -3.37-14.7%
20252025-12-31USD -3.473.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.60

+1.2%

Gross Margin

N/A

N/A

Market Cap

$2.88BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.70

+2.3%

Employees

289

+1.5%

Net Income

-$178.56

+1.6%

EBITDA

-$181.06

+1.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$909.46

+50.0%

Total Debt

$233.35

+1.9%

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$213.83

+1.8%

Short Term Debt

$19.52

+3.9%

Return on Assets

-60.29%

+1.1%

Return on Invested Capital

-78.64%

+1.1%

Free Cash Flow

-$131.80

+1.4%

Operating Cash Flow

-$130.29

+1.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,777.74+0.01%
^DJIDJI
$51,304.21+0.00%
^IXICNASDAQ
$27,461.27+0.01%
BTCBitcoin
$85,510.00+0.00%

Questions About DYN

What is the current price of Dyne Therapeutics?

Dyne Therapeutics is trading at $15.21 per share.

What is the 52-week range for Dyne Therapeutics?

Over the past 52 weeks, Dyne Therapeutics has traded between $12.77 and $27.31.

How much debt does Dyne Therapeutics have?

As of the most recent reporting period, Dyne Therapeutics reported total debt of $233.35M.

How much cash does Dyne Therapeutics have on hand?

Dyne Therapeutics reported $676.11M in cash and cash equivalents in its most recent financial results.

What is Dyne Therapeutics’s dividend yield?

Dyne Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.